These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 25259743)

  • 1. Paricalcitol and endothelial function in chronic kidney disease trial.
    Zoccali C; Curatola G; Panuccio V; Tripepi R; Pizzini P; Versace M; Bolignano D; Cutrupi S; Politi R; Tripepi G; Ghiadoni L; Thadhani R; Mallamaci F
    Hypertension; 2014 Nov; 64(5):1005-11. PubMed ID: 25259743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum phosphate modifies the vascular response to vitamin D receptor activation in chronic kidney disease (CKD) patients.
    Zoccali C; Torino C; Curatola G; Panuccio V; Tripepi R; Pizzini P; Versace M; Bolignano D; Cutrupi S; Ghiadoni L; Thadhani R; Tripepi G; Mallamaci F
    Nutr Metab Cardiovasc Dis; 2016 Jul; 26(7):581-589. PubMed ID: 27113290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paricalcitol, Microvascular and Endothelial Function in Non-Diabetic Chronic Kidney Disease: A Randomized Trial.
    Lundwall K; Jörneskog G; Jacobson SH; Spaak J
    Am J Nephrol; 2015; 42(4):265-73. PubMed ID: 26496210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of paricalcitol on endothelial function and inflammation in type 2 diabetes and chronic kidney disease.
    Thethi TK; Bajwa MA; Ghanim H; Jo C; Weir M; Goldfine AB; Umpierrez G; Desouza C; Dandona P; Fang-Hollingsworth Y; Raghavan V; Fonseca VA
    J Diabetes Complications; 2015 Apr; 29(3):433-7. PubMed ID: 25633573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vitamin D receptor activation by paricalcitol and insulin resistance in CKD.
    Spoto B; Pizzini P; Cutrupi S; Tripepi G; Curatola G; Mallamaci F; Zoccali C
    Nutr Metab Cardiovasc Dis; 2018 Mar; 28(3):291-297. PubMed ID: 29307660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial.
    Fishbane S; Chittineni H; Packman M; Dutka P; Ali N; Durie N
    Am J Kidney Dis; 2009 Oct; 54(4):647-52. PubMed ID: 19596163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vitamin D receptor activation raises soluble thrombomodulin levels in chronic kidney disease patients: a double blind, randomized trial.
    D'arrigo G; Pizzini P; Cutrupi S; Tripepi R; Tripepi G; Mallamaci F; Zoccali C
    Nephrol Dial Transplant; 2019 May; 34(5):819-824. PubMed ID: 29668990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Experience with active vitamin D metabolites in phosphorus-calcium metabolic disorders in patients with predialysis chronic kidney disease].
    Milovanova LIu; Dobrosmyslov IA; Milovanov IuS
    Ter Arkh; 2014; 86(6):52-6. PubMed ID: 25095656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of paricalcitol on calcium and phosphate metabolism and markers of bone health in patients with diabetic nephropathy: results of the VITAL study.
    Coyne DW; Andress DL; Amdahl MJ; Ritz E; de Zeeuw D
    Nephrol Dial Transplant; 2013 Sep; 28(9):2260-8. PubMed ID: 23787544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FGF23 and the PTH response to paricalcitol in chronic kidney disease.
    D'Arrigo G; Pizzini P; Cutrupi S; Tripepi R; Tripepi G; Mallamaci F; Zoccali C
    Eur J Clin Invest; 2020 Feb; 50(2):e13196. PubMed ID: 31863599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial.
    Thadhani R; Appelbaum E; Pritchett Y; Chang Y; Wenger J; Tamez H; Bhan I; Agarwal R; Zoccali C; Wanner C; Lloyd-Jones D; Cannata J; Thompson BT; Andress D; Zhang W; Packham D; Singh B; Zehnder D; Shah A; Pachika A; Manning WJ; Solomon SD
    JAMA; 2012 Feb; 307(7):674-84. PubMed ID: 22337679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paricalcitol reduces proteinuria but does not modify peritoneal protein loss in patients on peritoneal dialysis.
    Sánchez-Álvarez JE; Rodríguez-Suárez C; Coronel-Aguilar D; González-Díaz I; Núñez-Moral M; Peláez-Requejo B; Fernández-Viña A; Quintana-Fernández A
    Nefrologia; 2013 Jan; 33(1):70-6. PubMed ID: 23364628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating adiponectin modifies the FGF23 response to vitamin D receptor activation: a post hoc analysis of a double-blind, randomized clinical trial.
    Spoto B; Pizzini P; Tripepi G; Mallamaci F; Zoccali C
    Nephrol Dial Transplant; 2018 Oct; 33(10):1764-1769. PubMed ID: 29304245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiproteinuric effect of oral paricalcitol in chronic kidney disease.
    Agarwal R; Acharya M; Tian J; Hippensteel RL; Melnick JZ; Qiu P; Williams L; Batlle D
    Kidney Int; 2005 Dec; 68(6):2823-8. PubMed ID: 16316359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vitamin D and methylarginines in chronic kidney disease (CKD).
    Torino C; Pizzini P; Cutrupi S; Tripepi R; Tripepi G; Mallamaci F; Zoccali C
    PLoS One; 2017; 12(10):e0185449. PubMed ID: 28976989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of oral paricalcitol therapy on arterial stiffness and osteopontin in hypertensive patients with chronic kidney disease and secondary hyperparathyroidism.
    Giakoumis M; Tsioufis C; Dimitriadis K; Sonikian M; Kasiakogias A; Andrikou E; Kalos T; Konstantinidis D; Filis K; Petras D; Tousoulis D
    Hellenic J Cardiol; 2019; 60(2):108-113. PubMed ID: 29305902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of paricalcitol in children with stages 3 to 5 chronic kidney disease.
    Webb NJA; Lerner G; Warady BA; Dell KM; Greenbaum LA; Ariceta G; Hoppe B; Linde P; Lee HJ; Eldred A; Dufek MB
    Pediatr Nephrol; 2017 Jul; 32(7):1221-1232. PubMed ID: 28332096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of paricalcitol on mineral bone metabolism in kidney transplant recipients with secondary hyperparathyroidism.
    Borrego Utiel FJ; Bravo Soto JA; Merino Pérez MJ; González Carmelo I; López Jiménez V; García Álvarez T; Acosta Martínez Y; Mazuecos Blanca MA
    Nefrologia; 2015; 35(4):363-73. PubMed ID: 26306956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of paricalcitol on left ventricular mass and function in CKD--the OPERA trial.
    Wang AY; Fang F; Chan J; Wen YY; Qing S; Chan IH; Lo G; Lai KN; Lo WK; Lam CW; Yu CM
    J Am Soc Nephrol; 2014 Jan; 25(1):175-86. PubMed ID: 24052631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis.
    Greenbaum LA; Benador N; Goldstein SL; Paredes A; Melnick JZ; Mattingly S; Amdahl M; Williams LA; Salusky IB
    Am J Kidney Dis; 2007 Jun; 49(6):814-23. PubMed ID: 17533024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.